Vaccine procurement during an influenza pandemic and the role of Advance Purchase Agreements: Lessons from 2009-H1N1 by Eccleston-Turner, MR
Vaccine procurement during an influenza pandemic and the role of Advance 
Purchase Agreements: lessons from 2009-H1N1 
Vaccines are hugely important tools in minimising the effect pandemic influenza could 
have on a population. The reforms introduced by the Pandemic Influenza Preparedness 
Framework are ill-suited to providing sufficient levels of access to vaccines to meet the 
needs of developing states, and as such developing states will continue to be reliant 
upon the traditional methods of vaccine procurement to procure the majority of the 
vaccines they required. Using procurement during 2009-H1N1 as a case study, this 
paper examines the methods of procurement utilised by states in order to determine if 
the procurement tools available to developing states are sufficient to procure adequate 
levels of pandemic influenza vaccines.  Particular focus is given to the role Advance 
Purchase Agreements play in the procurement process. By exploring this case study it is 
possible to argue that these procurement methods are ineffective for developing states, 
and when the next influenza pandemic occurs, demand will once again outstrip supply 
globally, due to supply of vaccines being dominated by the developed states with 
Advance Purchase Agreements in place.   
Keywords: procurement; pandemic influenza; global health; access to 
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Introduction 
Challenges in vaccine procurement arise when a vaccine is in short supply, and in high 
demand by many states at the same time, as is the case with pandemic influenza 
vaccines. Numerous factors make such a scenario particularly concerning, including: 
firstly, pandemic influenza can spread locally, nationally and globally in a matter of 
weeks (Colizza, Barrat, Barthelemy, Valleron, Vespignani, 2007; Bonabeau, Toubiana & 
Flahault 1998). The first case of 2009-H1N1 was confirmed on April 24th 2009 in 
Mexico (WHO, 2009a), only one month later forty-six states had reported a total of 
12,515 cases (WHO, 2009b); secondly, there is a delay between the pandemic being 
declared, and doses of a vaccine being administered. During 2009-H1N1 the first 
vaccination was administered three months after the pandemic was announced (Parry, 
2009). These factors coupled with the high levels of mortality and morbidity (World 
Health Organization, 2010) that may be associated with influenza pandemics 
(Kilbourne, 2006) means that those pandemic influenza vaccines which can be 
manufactured may be in demand by many states as soon as they are available, each 
seeking to access to enough vaccine to meet the needs of the population. 
The access and distribution system for pandemic influenza vaccines has garnered 
significant criticism within the literature (Coker & Mounier-Jack, 2006, Lee & Fidler, 
2007), and developing states. Most notably in 2005, the Indonesian Government refused 
to share samples of H5N1 with the WHO, and cited an unfair correlation between 
sharing samples with the WHO and the benefits obtained in return 
(Sedyaningsih, Isfandari, Soendoro, Supari , 2008). The Indonesian Health Minister at 
that time claimed that the WHO passed the samples they had provided onto 
pharmaceutical companies to develop unaffordable commercial vaccines (Butler, 2007).  
This incident acted as a major impetus for the creation of the WHO PIP Framework, 
which is considered below.  
This paper is a case study on the procurement of pandemic influenza vaccines during 
2009-H1N1, and the likely manner in which procurement will occur during future 
pandemics. This case study serves to highlight how inefficient the procurement methods 
for pandemic influenza vaccines are for developing states, and the role Advance 
Purchase Agreements play in allowing developed states to dominate the supply of 
vaccine during a pandemic.  
The Traditional Methods of Vaccine Procurement 
Vaccines are obtained by states for their public health vaccination programmes using 
four principle procurement methods, which are outlined below.  
Self-Procurement Directly by State 
Self-procurement, the process of vaccines being purchased from manufacturers directly 
by governments, represents the majority of vaccines that are procured worldwide (79%) 
(WHO-UNICEF, 2012). Self-procurement has a number of distinct benefits for 
governments.  It allows for the independent selection of manufacturer, which may result 
in the negotiation of lower unit price, and increased responsiveness to health needs 
within a state.  Such benefits may not be replicable to states who procure via donations, 
as they rely on the vaccine selection and procurement methods of the donor 
organisation.  
If a government wishes, and has the ability, to self-procure vaccines, additional 
technical elements of the procurement process must be managed by the state. These 
include pre-qualification or product licencing, the efficiency of which is considered to 
be a high priority for the WHO (WHO, 2007); preparation of bidding documents and 
realisation of the tender; selection of supplier; financial arrangements; and contract and 
quality monitoring (WHO, 2003). Managing the procurement process requires 
specialised technical knowledge in the fields of medicine and law, the financial 
resources to purchase the vaccines, and an appropriate certification process for licensing 
vaccine safety and efficacy.  In the case of influenza vaccines, an appropriate cold-chain 
infrastructure is also required to store the vaccines. Such advanced infrastructure, 
knowledge and technical ability (Hinman, 2013) is beyond the capacity of many 
developing states (Hyde, 2012).  For example, the African Region of the WHO is 
considered to have the weakest infrastructure (WHO, 2012a) in terms of legislative 
framework and financing, preparedness, and public health emergency response (WHO, 
2012b). However, in some instances, if a developing state is using an international 
organisation as a procurement agent, some degree of technical assistance from 
international organisations may be available for such matters (GAVI, 2011). 
Advance Purchase Agreements and Vaccine Procurement 
Of particular relevance to some self-procuring states are Advance Purchase Agreements 
(APAs). APAs for vaccine procurement take the form of ‘sleeping contracts’; a contract 
between two parties (in this case, a vaccine manufacturer and a government) which lays 
dormant and unenforceable until triggered by a pre-determined event, at which stage it 
becomes legally binding (Kremer & Glennerster, 2004). The impact APAs have on 
procurement of pandemic influenza vaccines is considered below.  
Donations via international organisations 
As the previous method of self-procuring vaccines on the open market from 
manufacturers is beyond the healthcare budgets of some developing states (Lu et al, 
2010; Mahoney, Ramachandran, and Xu 2000; Levine et al, 2011; Hargreaves et al, 
2011), a number of non-governmental and inter-governmental organisations, such as the 
GAVI Alliance (GAVI, 2011b), World Health Organisation (WHO, 2011b), and 
UNICEF (UNICEF, 2012) provide vaccines to governments. These international 
organisations acquire vaccines through a number of routes: donations from 
manufacturers (Towse et al, 2012) and states (WHO, 2011b), or by acting as a 
procurement agent, purchasing the vaccines directly from the manufacturers either using 
their own finances, or using finances provided by the states they are procuring on behalf 
of (World Bank, 2003; DeRoeck et al, 2006). Vaccines are then provided to developing 
states that lack the capacity to self-procure.  
Procured and administered by international organisations 
In some instances, international organisations procure the vaccines and administer them 
to populations directly (WHO, UNICEF & the World Bank, 2009). This predominantly 
occurs when a state lacks the necessary infrastructure to administer the vaccines. In 
these cases the procurement methods of an international organisation are utilised in the 
same manner as outlined above, but rather than providing vaccines to a government for 
administration, representatives of the international organisation coordinate, manage and 
administer the vaccines to the population (Ciglenecki et al, 2013).  
Procured via other sources 
Inter-state donations are made directly from one state to another, without using an 
international organisation as a procurement agent. Inter-state sale of vaccines is where 
one state sells some vaccine to another. Inter-state sales of vaccines are quite rare, 
although they did occur during the 2009-H1N1 influenza pandemic, as the case study 
below discusses.  
Vaccine Procurement during an Influenza Pandemic: Case study on 2009-H1N1 
All pandemic influenza vaccines are procured by the national government, and then 
administered to the population, either in line with the national policy on pandemic 
influenza management, if the state has one, or on an ad-hoc basis. Therefore, the role of 
the national government in introducing vaccines into a health system is particularly 
significant during an influenza pandemic. When faced with an influenza pandemic, 
immunising ‘at risk’ populations as soon as possible should become a major public 
health priority (Mounier-Jack & Coker, 2006; Uscher-Pines et al, 2006; WHO, 2005). 
The number of doses which would be required in order for all states to immunise just 
the ‘at risk’ populations is much higher than the amount which can be manufactured in 
the first year of pandemic influenza vaccine manufacturing; WHO currently define at 
risk groups for influenza vaccines as being ‘pregnant women, health-care workers, the 
elderly, those with risk conditions and children aged 6-59 months’ (WHO, 2012d) but 
the demographic can change with different pandemic strains. Just within the USA it is 
estimated that approximately 159 million people fall into one or more of the WHO’s 
risk groups for the purposes of influenza vaccination (Swendiman & Jones, 2009), in 
the European Union that figure rises to 248.3 million (Ryan et al, 2006), and the 
maximum number of vaccines that can be manufactured and distributed within the first 
year of the pandemic is just over one billion doses (Partridge & Kieny, 2013). 
Therefore, even on a one-dose vaccination schedule there are insufficient vaccine 
available to cover the global ‘at risk’ population, on a two-dose schedule, there are 
scarcely enough vaccine manufactured to immunise the at risk population in the EU & 
the USA.  
Self-Procurement During 2009-H1N1 
During an influenza pandemic, states are significantly more likely to obtain vaccines, 
and obtain them earlier in the pandemic if they self-procure, as opposed to being reliant 
on donations. Four-times as many vaccines were self-procured during 2009-H1N1 than 
were donated during the same pandemic (WHO, 2013), and donated vaccine arrived in 
states at least four months after self-procuring states (Partridge & Kieny, 2010). The 
fundamental problem facing many developing states reliant upon international 
organisations for vaccine donations is that a majority of this finite amount of pandemic 
influenza vaccines which can be manufactured in the first year is already reserved and 
guaranteed through Advance Purchase Agreements held by many developed states 
(Verweij, 2009; Hanquet, 2010; Fidler, 2010), or large quantities of the supply is bought 
by developed states early on in the pandemic. As a result, developing states and 
international organisations are reliant upon donations from vaccine manufacturers and 
states with excess vaccines to sell or donate in order to immunise their populations.  
The Role of Advanced Purchase Agreements during 2009-H1N1 
APAs for pandemic influenza vaccines are made enforceable by a Phase Six pandemic 
declaration being made by the WHO. A Phase Six declaration is defined as being when: 
sustained human-to-human spread of the virus into at least two countries in one WHO 
region, with community level outbreaks in at least one other country in a different WHO 
region. Designation of this phase will indicate that a global pandemic is under way. 
(WHO, 2010d) 
The terms of APAs are broad enough to allow governments to reserve doses of vaccine 
to treat a disease sub-type that may not yet have come into existence. The APA which 
the government of the United Kingdom had in place before the 2009-H1N1 pandemic 
allowed the government to purchase 132 million doses from two manufacturers 
(Parliamentary Office for Science and Technology, 2009). However, the minimum 
number of vaccines procured via an APA appears to have some degree of flexibility. 
When it became apparent that the 2009-H1N1 pandemic was not as severe as 
anticipated, a number of states with APAs in place attempted to reduce their allocation; 
of the eleven states in Europe that attempted to reduce their allocation, all but two were 
allowed to do so by the manufacturers (European Centre for Disease Prevention and 
Control, 2011). In terms of pandemic preparedness and response, such a degree of 
flexibility was clearly highly beneficial to states with APAs in place during 2009-H1N1 
in that it allowed a number of states to guarantee the delivery of the maximum number 
of doses during a particularly severe pandemic, and to reduce their number of 
guaranteed doses during a less severe pandemic. 
Advance Purchase Agreements for pandemic influenza vaccines appear to be common 
amongst developed states.  During 2009-H1N1, of the 53 developed states within the 
World Trade Organisation, 20 states had an APA in place. Within the European Union 
alone, sixteen countries had an APA in place prior to the start of the outbreak, and APAs 
were utilised by Canada, Switzerland, America, and New Zealand  during 2009-H1N1. 
(European Centre for Disease Prevention and Control, 2011; Public Health Agency of 
Canada, 2012; WHO, 2008, Department of Health and Human Services , 2010; Ministry 
of Health (NZ), 2009) 
The WHO has encouraged use of APAs by developing states, in order to ‘increase 
equity in supply and support advance planning for administration of vaccines.’ (World 
Health Organisation, 2012b), and commitments have been made from pharmaceutical 
companies such as GlaxoSmithKline that they ‘would supply [vaccines via an APA] at 
tiered prices, based on the gross national income of the nation’ (GSK, 2011; GSK 
2008). Despite this, it may still be unrealistic to expect states with limited healthcare 
budgets (a fact noted by GlaxoSmithKline (GSK, 2008)) to spend a large proportion of 
that budget on maintaining a contract that guarantees vaccines for a pandemic which 
may not occur in the next five, ten, or even twenty years. This is particularly noticeable 
given that the per capita government expenditure on healthcare has an average of 
$12USD in least-developed states, $56.8USD in low-middle income (developing) 
states, $275USD in upper-middle income (developing) states and $2,186USD in 
developed states (WHO, 2012c).  
APA are maintained by states paying an annual ‘Pandemic Preparedness Fee’ to the 
manufacturer. Whilst the exact costs of maintaining an APA by way of a Pandemic 
Preparedness Fee are not publicly available, a system whereby states are required to pay 
to maintain contracts for vaccines that may not even be required over the course of the 
contract’s life may be financially prohibitive, or not fit the spending priorities for many 
developing states. On the point of costs, it was confirmed during a UK House of Lords 
Science and Technology Committee report into the UK pandemic preparedness plans 
that whilst the vaccines for pandemic influenza which are reserved via an APA are paid 
for at the point of purchase during a pandemic, during the dormant phase the 
Agreements are maintained by the government paying ‘Pandemic Preparedness Fees’ to 
maintain the contract (House of Lords Science and Technology Committee, 2005). At 
the time the report was drafted the Minster responsible claimed it was ‘rather difficult to 
give exact figures’ as to the cost of the Pandemic Preparedness Fee associated with 
maintaining the UK’s APA, as negotiations were still ongoing (House of Lords Science 
and Technology Committee, 2005). A Freedom of Information request made to the 
Department of Health to determine the cost of the Pandemic Preparedness Fee was 
refused on the basis that making such information available could “potentially limit the 
contractor’s negotiating position with other customers if this information was put in the 
public domain” (communication held on file by the author, 2014). Full access to the 
terms of developed state’s APA’s would provide an avenue of potential future research 
in this field, in order to determine the exact impact such agreements have on access.  
During 2009-H1N1, many Advance Purchase Agreements held by developed states 
were triggered, providing them with guaranteed priority access to vaccines. These states 
also bought vaccines to cover a large proportion of their population in the early stage of 
the 2009-H1N1 influenza pandemic. Vaccine manufacturers were unable to take or fulfil 
orders from many developing states, or international organisations on behalf of 
developing states, in the early stages of production.  It is estimated that it will take 
approximately one year for vaccine manufacturers to complete all APA orders, if no 
states reduce their APA allocation (Parliamentary Office for Science and Technology, 
2009).  
The impact APAs have on access to vaccine during a pandemic appears to be 
significant. A 2009 survey by the World Health Organisation of pandemic influenza 
vaccine manufacturers asked whether they would be willing to reserve 10% of real-time 
production for acquisition by United Nations agencies, 14 out of 25 were unable to meet 
the request to set aside 10% of their production capacity, because they were constrained 
by meeting the volume of vaccines reserved via APAs (Collin & de Radiguès, 2009). 
Despite the changes made to vaccine procurement by the PIP Framework, it appears as 
if the commitment to supply 10% of real-time vaccine manufacturing capacity to the 
WHO under the PIP Framework has not altered the impact APAs will have on access to 
vaccines during the next pandemic. APA contracts that are in place during the next 
pandemic will be serviced alongside the 10% of vaccine production committed to 
WHO, however, the vaccine reserved via APAs will be distributed prior to orders from 
states without APAs in place. Given the fact that APAs are only held by developed 
states, it appears that middle-income and developing states will predominantly be 
inhibited from accessing vaccine due to these agreements.  
Donated Vaccine During 2009-H1N1 
Australia, Canada, the USA, the UK, Japan, France and the Netherlands were some of 
the first states to receive vaccine during 2009-H1N1 (Verweij 2009), and in an attempt 
to increase access to vaccines for developing states the WHO requested these states to 
donate a proportion of the vaccine to them to distribute to developing nations at risk of 
the outbreak (WHO, 2011b). However, it was noted that “WHO and developing 
countries had little leverage to influence developed countries other than rhetoric about 
equity, justice, and solidarity” (Fidler, 2010 p.2). Despite the fact that nearly 120 million 
doses were pledged to the WHO by the USA, Australia, Brazil, France, Italy, New 
Zealand, Norway, Switzerland, and the UK (WHO, 2011b), these states only began 
shipping doses after it became apparent that a one-dose regime would suffice to 
immunise adults. This halved the amount of vaccine these states would require to meet 
immunisation goals (WHO, 2011b), and coincided with the confirmation that the threat 
posed by the 2009-H1N1 was not as severe as first thought (Neuzil, 2009; Greenberg et 
al, 2009; Clark et al, 2009; BBC News, 2009). The outcome of the two major studies 
considering the efficacy of a one-dose strategy (Greenberg et al, and Clark et al) were 
made available on 17th December 2009, and the first shipments of donated vaccine 
arrived in recipient states in late January 2010 (WHO, 2011b) despite the fact that it had 
been available in developed states, in comparatively much larger quantities, since 
October 2009 (Schwarzinger et al , 2010; CDC, 2010). 
In addition to the doses pledged to the WHO, some developed states with excess 
vaccine commenced inter-state sales of vaccine during 2009-H1N1. In November 2009 
the Netherlands announced the sale of fifty-five per cent of the vaccines for 2009-H1N1 
that they had procured via their APA; the following month Germany placed just over 
four per cent of their APA allocation on the open market, and in January 2010 France 
announced that ‘part’ of their allocation would be sold to other states. (BBC News, 
2010) 
As 2009-H1N1 was not as severe as initially anticipated, vaccine uptake was low in 
these states, and only a one-dose vaccination strategy was required to provide immunity, 
whereas a two-dose strategy is more common (Fauci, 2006); as a result, there were 
excess vaccine doses in several states who had procured vaccine early on in the 
pandemic. Such factors clearly made governments’ decision to sell, or donate purchased 
vaccines easier (Fidler, 2010).  
It appears as if the move to a one dose strategy, meaning that some developed states 
held excess doses of the vaccine, may have factored in the decision making process of 
some donor states. For example, US Health and Human Services Secretary, Kathleen 
Sebelius, told the Associated Press that “as the US is flush enough [with vaccines, now 
that a one-dose strategy will suffice] the long-promised donation of 25 million doses to 
developing countries is ready to ship.”(Neergaard, 2010). Furthermore, the 
commitments to donate vaccines which were made by manufacturers during 2009-
H1N1 were made without specifying a delivery date or timeframe, despite the fact that 
these manufacturers were already producing and shipping vaccine to self-procuring 
states when the pledge to donate was made.  
Developing states being reliant upon manufacturers and developed states to donate 
vaccines for their population during an influenza pandemic resulted in a scenario 
whereby during the 2009-H1N1 outbreak when the WHO distributed 78 million doses 
of pandemic influenza vaccine (donated by vaccine manufacturers and states with 
excess supply), over 30 million of these doses were delivered to developing states at 
least three months later than developed states in the ‘post-pandemic phase’ (WHO, 
2011b), when the virus’ transmission levels and intensity is considered more akin to a 
seasonal influenza outbreak, than that of a pandemic (WHO, 2014).  
During these three months a further 7000 deaths were recorded from 2009-H1N1 by the 
World Health Organization, predominantly in developing states (WHO, 2009b). Whilst 
this is a relatively low figure, when compared with the population of developing states, 
it is worth bearing in mind that 2009-H1N1 was a particularly mild pandemic (WHO, 
2013;) when compared with previous influenza pandemics (Kilbourne, 2006), and 
during a more severe pandemic the number of deaths during this period would have 
certainly have been higher. Moreover, the fact that international organisations were 
solely reliant upon the goodwill of states with excess vaccines or manufacturers for 
donations of vaccines, is particularly concerning. During a more severe pandemic in the 
future, those states that have purchased or reserved vaccines for their own population 
may very well be reluctant to donate or sell them.  
Fig1. Distribution and sources for pandemic A(H1N1) 2009 vaccine doses, by region† 
!  
Table reproduced from: (World Health Organization, 2013) 
AFR – African Region; AMR - Region of the Americas; EMR – Eastern Mediterranean 
Region; EUR – European Region; SEAR – South- East Asian Region; WRP – Western 
Pacific Region 
As can be seen from figure 1, during the 2009-H1N1 pandemic over 634 million doses 
of vaccine were procured by states. The majority of vaccines obtained by states were via 
central government purchases (59.4%), with 28.3% vaccines being procured from other 
sources, and 12.3% of vaccines deployed internationally being donated via the WHO’s 
Vaccine Deployment Initiative (VDI). The VDI was a department within the WHO 
charged with managing and coordinating the global donation of 2009-H1N1 vaccines, 
and the resources needed to deploy them, and was created specifically to manage the 
distribution of vaccines for 2009-H1N1. Although only 12.3% of vaccines were donated 
by the WHO, donations accounted for 94.5% of the African Region’s vaccines, 91.2% 
of vaccines utilised in the South-East Asia Region. Although all regions acquired some 
vaccines via self-procurement, this ranged from 98.8% in Europe, to only 6.5% in 
Africa.  
Self-procurement dominated the supply of vaccines during 2009-H1N1, and a state was 
much more likely to obtain vaccines if they self-procured, rather than if they were 
reliant upon donations. This can be demonstrated by considering the European and 
African Regions’ experience during 2009-H1N1 who at the time of the outbreak had 
fairly similar populations of around 800 million people (WHO, 2010c; OECD, 2010), 
but the procurement methods utilised by the states within these regions differed 
significantly. European states acquired 98.8% of their vaccines via self-procurement, 
and procured enough to immunise 27.5% of their population on a one dose strategy 
(WHO, 2013). Whereas in Africa 94.5% of the vaccines utilised were donated by the 
WHO, but only 3.9% of the population was immunised (WHO, 2013).   
Post 2009-H1N1 Developments  
The Pandemic Influenza Preparedness Framework  
The methods by which states pandemic influenza vaccine donations were gathered and 
managed were subject to reform in 2011, with the introduction of the Pandemic 
Influenza Preparedness Framework (PIP Framework) via the WHO. The WHO has long 
played an integral role in the response to influenza pandemics Gostin, 2014: P.367-378), 
although the effectiveness of the   The PIP Framework sets out to increase access to 
pandemic influenza vaccines by enabling the WHO to manage a stockpile of around 150 
million vaccines; “50 million doses of the stockpile will be for use in ‘affected 
countries, according to public health risk and need, to assist in containing the first 
outbreak or outbreaks of an emerging pandemic and 100 million for distribution….to 
developing countries that have no or inadequate access to....influenza vaccines, on a per 
capita basis that can be distributed to affected and at risk developing states during a 
pandemic” (WHO, 2011a). 
 This stockpile is created by requiring vaccine manufacturers who receive pandemic 
influenza virus samples from the WHO for vaccine development, to conclude a 
Standard Material Transfer Agreement (SMTA2). In these Agreements, in return for 
receiving virus samples, manufacturers commit to at least two of the following: 
“Donate at least 10% of real time pandemic vaccine production to WHO.  
Reserve at least 10% of real time pandemic vaccine production at affordable prices to 
WHO.  
Donate at least X treatment courses of needed antiviral medicine for the pandemic to 
WHO.  
Reserve at least X treatment courses of needed antiviral medicine for the pandemic at 
affordable prices”. (WHO, 2011a) 
So far, only two out of twenty-five influenza vaccine manufacturers, have concluded 
SMTA2 Agreements (WHO, 2012e), and despite the PIP Framework claiming 
manufacturers must donate or reserve at least 10% of real time vaccine production, 
GSK have committed to donating 7.5% and reserving 2.5% of their production (Along 
with donating 2 million doses of antivirals and reserving 8 million doses of antivirals at 
affordable prices) (WHO, 2012f), and Sanofi Pasteur have committed to donating 7.5% 
and reserving 7.5% of their real-time pandemic influenza vaccine production (WHO, 
2012g). The fact that so few SMTA2 Agreements have been concluded, and those that 
have, appear to have weaker than anticipated commitments on the part of vaccine 
manufacturer’s points towards the lack of impact the Framework will have on access to 
vaccine. There is an ongoing need to monitor the content of the SMTA2 Agreements 
that are concluded, and determine to what extend they differentiate from the terms laid 
down by the WHO in the Framework.  
A number of commentators have expressed concerns that the benefit sharing 
requirements of the Framework will not result in significant improvements in access to 
vaccine during a pandemic for developing states for two principal reasons. Firstly, the 
Framework has only imposed minimal changes on the existing market-based economy 
surrounding influenza vaccine production and procurement (Kamradt-Scott & Lee, 
2011).  Secondly, initiatives to encourage donations of vaccine to the WHO, similar to 
those detailed in the Framework, have already been implemented outside of the 
Framework without significantly improving access to vaccine for developing states 
(Vezzani, 2010). 
The idea that the PIP Framework has done little to change the market-based economy 
for vaccines, and will therefore have very little impact upon developing states ability to 
offer national vaccination programmes, and the benefit-sharing system in the 
Framework appears to be wholly insufficient to rectify inequities in access to vaccines 
during a pandemic. As Rhodes states: ‘In terms of a simple calculation, the 100 million 
doses from the stockpile that will be allocated to developing countries on a per capita 
basis, would, even if a single dose regime was viable, cover approximately 1.8% of 
their populations.’ (Rhodes, 2012) 
Whilst the true impact of the Framework will not be seen until it is utilised during an 
influenza pandemic, it is likely the impact it could have will be somewhat negligible, 
and the need for states to procure at least some, if not the majority, of their vaccines via 
the traditional procurement methods will continue. In light of this, the methods by 
which states procure vaccines outside of the PIP Framework, and the impact these 
procurement methods have on the likelihood of a state obtain vaccine during an 
influenza pandemic is crucial.  
Pandemic Influenza Manufacturing Capacity 
As this paper only considers vaccine procurement during 2009-H1N1 it would not be 
appropriate to draw absolute conclusions from it, and generalisations based on 2009-
H1N1 may have limited predicative power for a number of reasons.  Firstly, the global 
manufacturing capacity has expanded since 2009; the most recent survey of vaccine 
manufactures shows capacity grew from 876 million doses per annum in 2009 
(Partridge & Kieny, 2010), to 1420 million doses per annum in 2011 (Partridge & 
Kieny, 2013).  Secondly, 2009-H1N1 was not as severe as anticipated thereby 
increasing the number of vaccines which were available for developing states; there is 
no guarantee that developed states will behave in this manner should the next pandemic 
be more severe. 
Some generalisations from vaccine procurement during 2009-H1N1 may, however, be 
justified. As outlined at the introduction, the impact the Pandemic Influenza 
Preparedness Framework will have on access to vaccines during a pandemic looks to be 
limited. Furthermore, whilst manufacturing capacity has grown since 2009, 75% of this 
capacity is dedicated to meeting the needs of the ‘Northern Hemisphere’ (Partridge & 
Kieny, 2013).  While there have been changes to the manner in which the WHO 
procures vaccines for donation to developing states since 2009 via the PIP Framework, 
these will arguably have a limited impact overall, and vaccine procurement during the 
next pandemic will occur in a similar manner to 2009-H1N1. Finally, whilst influenza 
vaccine manufacturing capacity may have grown by 620 million doses between 2009 
and 2011, human population grew by 170 million in the same period from 6.81 billion 
(Population Reference Bureau, 2009) to 6.98 billion (Population Reference Bureau, 
2012), with population growth predominantly occurring in least-developed states 
(Population Reference Bureau, 2012). Whilst capacity grew faster than population 
during this period, it did not grow to such an extent that it will have a significant impact 
on access to vaccine if the next influenza pandemic occurs in the near future, and 
manufacturing capacity and population growth continue to follow the same trends.  
Conclusion  
The above factors mean that, despite the improvement the PIP stockpile may have on 
access to vaccines for developing states, when the next influenza pandemic occurs 
demand will once again outstrip supply amongst developing nations, in much the same 
way as occurred during 2009-H1N1. Aside from the small number of doses which 
developing state may be provided from the PIP stockpile, the traditional methods states 
use to procure vaccines during a pandemic will continue to result in a scenario whereby 
developing states are least likely to gain timely access to pandemic influenza vaccines 
on behalf of their populations; this means that during when the next influenza pandemic 
occurs it is unlikely that developing states are going to be in a significantly better 
position to procure the vaccines they need than they were during 2009-H1N1.   
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